- Home
- ADCT
ADCT
ADC Therapeutics SA
as 03-25-2025 12:30pm EST
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.
| Founded: | 2011 | Country: | Switzerland |
| Employees: | N/A | City: | EPALINGES |
| Market Cap: | 143.1M | IPO Year: | 2020 |
| Target Price: | $8.50 | AVG Volume (30 days): | 336.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.32 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.39 - $5.38 | Next Earning Date: | 05-05-2025 |
| Revenue: | $70,717,000 | Revenue Growth: | -42.30% |
| Revenue Growth (this year): | 6.81% | Revenue Growth (next year): | 11.24% |
Latest ADC Therapeutics SA News
ADCT Breaking Stock News: Dive into ADCT Ticker-Specific Updates for Smart Investing
PR Newswire
6 days ago
ADC Therapeutics to Host Fourth Quarter and Year-End 2024 Financial Results Conference Call on March 27, 2025
Zacks
a month ago
Tango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue Estimates
Zacks
a month ago
Beam Therapeutics Inc. (BEAM) Reports Q4 Loss, Tops Revenue Estimates
PR Newswire
2 months ago
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
PR Newswire
2 months ago
ADC Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference
PR Newswire
3 months ago
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
Simply Wall St.
3 months ago
Is ADC Therapeutics SA (NYSE:ADCT) Worth US$2.0 Based On Its Intrinsic Value?
MT Newswires
3 months ago
Update: ADC Shares Rise After Company Completes Enrollment in Late-Stage Zynlonta Combination Trial
Compare ADCT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ADCT ADC Therapeutics SA - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.